OS Therapies (NYSE:OSTX) Given Buy Rating at D. Boral Capital

OS Therapies (NYSE:OSTX)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They currently have a $20.00 price objective on the stock.

Separately, Maxim Group upped their target price on OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, January 16th.

OS Therapies Stock Down 5.6 %

Shares of NYSE:OSTX opened at $1.86 on Thursday. The business has a 50-day moving average of $3.36 and a two-hundred day moving average of $3.15. OS Therapies has a fifty-two week low of $1.58 and a fifty-two week high of $7.00.

Insider Buying and Selling at OS Therapies

In other OS Therapies news, major shareholder Shalom Auerbach sold 100,000 shares of OS Therapies stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $2.84, for a total value of $284,000.00. Following the transaction, the insider now directly owns 2,431,211 shares of the company’s stock, valued at $6,904,639.24. The trade was a 3.95 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Institutional Investors Weigh In On OS Therapies

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC purchased a new stake in OS Therapies Inc (NYSE:OSTX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.